.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,144,577

« Back to Dashboard

Claims for Patent: 7,144,577

Title:Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
Abstract:Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.
Inventor(s): Torres; Ramon A. (New York, NY)
Assignee: Applied Research Systems ARS (Curacao, NL)
Application Number:10/725,484
Patent Claims: 1. A method for treating HIV-associated dysmorphia/dysmetabolic syndrome (HADDS), comprising administering to a patient in need thereof an effective amount of a substance comprising: (a) human growth hormone releasing hormone (hGHRH); (b) a fragment of (a) that retains the ability to stimulate the release of growth hormone; (c) a variant or analog of (a) or (b) that retains the ability to stimulate the release of growth hormone; or (d) a functional derivative or salt of (a), (b) or (c) that retains the ability to stimulate the release of growth hormone.

2. The method of claim 1, wherein said substance is administered subcutaneously.

3. The method of claim 1, wherein said substance is administered intramuscularly.

4. The method of claim 1, wherein said HADDS is abnormal visceral adipose tissue (VAT) accumulation a said patient is a HIV/AIDS patient presenting abnormal visceral adipose tissue accumulation.

5. The method of claim 1, wherein said HADDS is dorsocervical adipose tissue accumulation ("buffalo hump") and said patient is a HIV/AIDS patient presenting dorsocervical adipose tissue accumulation ("buffalo hump").

6. The method of claim 1, wherein said HADDS is a type of pathological adipose accumulation associated with HADDS syndrome selected from the group consisting of abnormal accumulation of adipose tissue in submandibular ("horse collar"), supraclavicular, pectoral and/or mammary areas, and/or has lipomas (benign encapsulated fatty tumors, either single or multiple), and said patient is a HIV/AIDS patient presenting with one or more of these abnormal features.

7. The method of claim 1, wherein said substance comprises human growth hormone releasing hormone (hGHRH).

8. The method of claim 7, wherein said hGHRH has the amino acid sequence of SEQ ID NO:1.

9. The method of claim 1, wherein said substance comprises a fragment of (a) that retains the ability to stimulate the release of growth hormone.

10. The method of claim 9, wherein said fragment comprises amino acid residues 1 29 of SEQ ID NO:1.

11. The method of claim 9, wherein said fragment comprises amino acid residues 1 40 of SEQ ID NO:1.

12. The method of claim 1, wherein said substance comprises a variant or analog of (a) or (b) that retains the ability to stimulate the release of growth hormone.

13. The method of claim 12, wherein said variant or analog is a variant or analog of (a).

14. The method of claim 12, wherein said variant or analog is a variant or analog of (b).

15. The method of claim 12, wherein said variant or analog of (a) or (b) has at least 70% amino acid sequence identity to the hGHRH of SEQ ID NO:1 or a fragment thereof.

16. The method of claim 12, wherein said variant or analog of (a) or (b) has at least 80% amino acid sequence identity to the hGHRH of SEQ ID NO:1 or a fragment thereof.

17. The method of claim 12, wherein said variant or analog of (a) or (b) has at least 90% amino acid sequence identity to the hGHRH of SEQ ID NO:1 or a fragment thereof.

18. The method of claim 12, wherein said variant or analog of (a) or (b) has at least 95% amino acid sequence identity to the hGHRH of SEQ ID NO:1 or a fragment thereof.

19. The method of claim 1, wherein said substance is a functional derivative or salt of (a), (b), or (c) that retains the ability to stimulate the release of growth hormone.

20. The method of claim 19, wherein said substance is a functional derivative of (a).

21. The method of claim 19, wherein said substance is a functional derivative of (b).

22. The method of claim 19, wherein said substance is a functional derivative of (c).

23. The method of claim 19, wherein said substance is a salt of (a).

24. The method of claim 19, wherein said substance is a salt of (b).

25. The method of claim 19, wherein said substance is a salt of (c).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc